Thomas J. Herzfeld Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22	Closed	-$7.65K	–	346
2023 Q3	$7.65K	Hold	22	–	–	﹤0.01%	200
2023 Q2	$7.74K	Hold	22	–	–	﹤0.01%	196
2023 Q1	$6.93K	Hold	22	–	–	﹤0.01%	188
2022 Q4	$6.35K	Hold	22	–	–	﹤0.01%	203
2022 Q3	$6K	Hold	22	–	–	﹤0.01%	190
2022 Q2	$6K	Hold	22	–	–	﹤0.01%	200
2022 Q1	$6K	Hold	22	–	–	﹤0.01%	222
2021 Q4	$5K	Hold	22	–	–	﹤0.01%	281
2021 Q3	$4K	Hold	22	–	–	﹤0.01%	293
2021 Q2	$4K	Buy	22 +8	+57%	+$1.67K	﹤0.01%	302
2021 Q1	$3K	Hold	14	–	–	﹤0.01%	319
2020 Q4	$3K	Hold	14	–	–	﹤0.01%	278
2020 Q3	$3K	Hold	14	–	–	﹤0.01%	227
2020 Q2	$4K	Buy	+14	New	+$3.8K	﹤0.01%	247

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Thomas J. Herzfeld Advisors's VRTX Position: Q4 2023 in Review

Thomas J. Herzfeld Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 22 shares — an estimated $7.65K sold.

Thomas J. Herzfeld Advisors first reported a position in VRTX in Q2 2020 and held it in 14 quarters. The position peaked at $7.74K in Q2 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Thomas J. Herzfeld Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 22 Vertex Pharmaceuticals shares in Q4 2023, an estimated $7.65K.
Thomas J. Herzfeld Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 14 quarters.
Thomas J. Herzfeld Advisors's Vertex Pharmaceuticals position peaked at $7.74K in Q2 2023.
1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.